Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

At Raspadskaya mine an open fire was extinguished

4/19/23 RASP

Rosneft started pilot development of the Ichemma field

4/19/23 ROSN

All miners at Raspadskaya mine evacuated

4/19/23 RASP

Ozon made early redemption of bonds for $750 million

4/19/23 OZON

Rosneft will be allowed to export LNG

4/19/23 ROSN

Phosagro estimates new ammonia production complex at $1.5 billion

4/19/23 PHOR

Yandex Market opened a testing center for warehouse robots

4/19/23 YNDX

Morgan Stanley reported for Q1 2023

4/19/23 MS

Raspadskaya mine evacuates miners due to fire

4/19/23 RASP

Abbott profits nearly halved in Q1

4/19/23 ABT